Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    ly2181308
Show Display Options
Rank Status Study
1 Completed A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: LY2181308 sodium;   Drug: cytarabine;   Drug: idarubicin
2 Completed Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel;   Drug: LY2181308
3 Completed A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: docetaxel;   Drug: LY2181308 sodium;   Drug: Prednisone
4 Withdrawn A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: LY2181308

Indicates status has not been verified in more than two years